Publicacións nas que colabora con Javier Crespo García (23)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Physicians' Use of Digital Health Interventions in the Management of Nonalcoholic Fatty Liver Disease

    Clinics in Liver Disease, Vol. 27, Núm. 2, pp. 515-533

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

  4. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Impacto clínico y económico global de la enfermedad hepática por hígado graso no alcohólico

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 6, pp. 396-403

  3. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2018

  1. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System

    Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282

  4. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4

    Liver International, Vol. 37, Núm. 12, pp. 1823-1832

  5. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

  6. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2015

  1. Application of the Barcelona clinic liver cancer therapeutic strategy and impact on survival

    United European Gastroenterology Journal, Vol. 3, Núm. 3, pp. 284-293